A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway

Figure 6

Effects of the ruthenium-fluvastatin complex on cell viability of (a) MCF-7 cells and (b) MDA-MB-231 cells at 24 hours. (c) DAPI-stained MCF-7 cells after 24 hours of treatment with the ruthenium-fluvastatin complex. (d) DAPI-stained MDA-MB-231 cells after 24 hours of treatment with the ruthenium-fluvastatin complex.

(a)

(b)

(c)

(d)